"Benzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a BENZENE fused to IMIDAZOLES.
| Descriptor ID |
D001562
|
| MeSH Number(s) |
D03.633.100.103
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzimidazoles".
Below are MeSH descriptors whose meaning is more specific than "Benzimidazoles".
This graph shows the total number of publications written about "Benzimidazoles" by people in this website by year, and whether "Benzimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 2 | 4 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 8 | 5 | 13 |
| 2013 | 3 | 2 | 5 |
| 2014 | 5 | 2 | 7 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 3 | 6 |
| 2017 | 4 | 2 | 6 |
| 2018 | 0 | 4 | 4 |
| 2019 | 4 | 1 | 5 |
| 2020 | 0 | 2 | 2 |
| 2021 | 5 | 2 | 7 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 1 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzimidazoles" by people in Profiles.
-
The BK channel-NS1619 agonist complex reveals molecular insights into allosteric activation gating. Proc Natl Acad Sci U S A. 2026 Feb 03; 123(5):e2507707123.
-
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.
-
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. J Oncol Pharm Pract. 2026 Jun; 32(4):641-647.
-
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 06; 23(2):183-193.
-
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
-
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2023 01 01; 41(1):107-116.
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2022 06; 33(6):658.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol. 2021 11 10; 39(32):3633-3644.